Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-cash Items: 2014-2024

  • Coherus Oncology's Non-cash Items fell 34.22% to $24.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $24.6 million, marking a year-over-year decrease of 34.22%. This contributed to the annual value of $24.6 million for FY2024, which is 34.22% down from last year.
  • Per Coherus Oncology's latest filing, its Non-cash Items stood at $24.6 million for Q4 2024, which was down 34.22% from $37.4 million recorded in Q4 2023.
  • Coherus Oncology's 5-year Non-cash Items high stood at $72.4 billion for Q4 2020, and its period low was $24.6 million during Q4 2024.
  • Moreover, its 3-year median value for Non-cash Items was $37.4 million (2023), whereas its average is $37.8 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first spiked by 77,115.39% in 2020, then plummeted by 99.92% in 2021.
  • Coherus Oncology's Non-cash Items (Quarterly) stood at $72.4 billion in 2020, then crashed by 99.92% to $61.4 million in 2021, then fell by 16.12% to $51.5 million in 2022, then decreased by 27.38% to $37.4 million in 2023, then tumbled by 34.22% to $24.6 million in 2024.
  • Its last three reported values are $24.6 million in Q4 2024, $37.4 million for Q4 2023, and $51.5 million during Q4 2022.